StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Rating) in a research note published on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
EVOK opened at $0.39 on Monday. The company has a quick ratio of 7.38, a current ratio of 7.51 and a debt-to-equity ratio of 1.41. Evoke Pharma has a 52-week low of $0.36 and a 52-week high of $1.91. The company has a 50 day moving average of $0.54 and a two-hundred day moving average of $0.76. The company has a market cap of $12.84 million, a P/E ratio of -1.50 and a beta of 0.77.
Evoke Pharma (NASDAQ:EVOK – Get Rating) last released its quarterly earnings data on Tuesday, March 8th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter. Evoke Pharma had a negative return on equity of 154.99% and a negative net margin of 529.48%. The business had revenue of $0.36 million for the quarter.
About Evoke Pharma (Get Rating)
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females.
- Get a free copy of the StockNews.com research report on Evoke Pharma (EVOK)
- Simply Good Foods Stock is a Healthy Defensive Play
- 3 Tech Stocks to Buy for Retirement
- Poor Timing Will Put Delta Air Lines on Standby For Risk-Off Investors
- Schlumberger Analyst Coverage Drives Market Higher
- 3 Stocks Down Big in ’22 That Are Worth Buying
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.